Anti-HER2 Combination Found Effective in HER2-Altered Bile Duct Cancers

A chemotherapy-free combination of two anti-human epidermal growth factor receptor 2 (anti-HER2) agents brought clinically meaningful responses to patients with bile duct cancers testing positive for HER2 or with mutated HER2 in research from Japan reported at the EORTC-NCI-AACR 2024 Molecular Targets and Cancer Therapeutics Symposium held in Barcelona, Spain.   In the SGNTUC-019 Phase II basket study of 217 patients, who had a variety of previously treated solid tumors with HER2 overexpressed, amplified, or mutated, a combination of tucatinib with trastuzumab brought significant clinical responses among those with biliary tract tumors in addition to those with breast cancer.